Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer

Yuwen Zhou(National Cancer Center), Meng Qiu(Northeast Normal University), Ye Chen(Hebei Medical University), Dan Pu(Sichuan University), Jing Zhang(Xijing Hospital), Jiyan Liu(Zhejiang University), Hongfeng Gou(Sichuan University), Qiu Li(Macau University of Science and Technology), Bing Wu(Harvard University), Feng Bi(Tianjin University of Traditional Chinese Medicine)
Anti-Cancer Drugs
December 21, 2018
10.1097/cad.0000000000000726
Cited by 44

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
|Molecular Cancer|2021|461
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350